Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis)

Pier Mannuccio Mannucci, Massimo Vanoli, Ileana Forza, Maria Teresa Canciani, Raffaella Scorza

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Background and Objectives. Autoantibodies inactivating the von Willebrand factor (VWF) cleaving protease, ADAMTS-13, are among the most frequent causes of thrombotic thrombocytopenic purpura (TTP). We evaluated whether or not ADAMTS-13 deficiency and autoantibodies inactivating the protease prevalent in patients with the prototypic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Design and Methods. We measured, in parallel, the protease and VWF antigen (VWF:Ag) in 123 patients, 36 of whom had SLE and 87 of whom had SSc. In 14 patients with either disease who had low plasma protease levels (below 40%) we also looked for anti-ADAMTS-13 inactivating antibodies. Results. ADAMTS-13 levels were significantly lower in SLE (p=0.0013) and in SSc (p=0.0002) than in normal controls. No anti-ADAMTS activity was measurable in patients with low ADAMTS-13 levels. VWF: Ag was high in both SLE and SSc (p=0.001). Interpretation and Conclusions. Systemic connective tissue diseases are other conditions besides TTP that are associated in some instances with low but detectable levels of ADAMTS-13. Autoantibodies inactivating protease activity are not the cause of the low plasma levels of ADAMTS-13.

Original languageEnglish
Pages (from-to)914-918
Number of pages5
JournalHaematologica
Volume88
Issue number8
Publication statusPublished - Aug 1 2003

Fingerprint

Connective Tissue Diseases
Systemic Scleroderma
Systemic Lupus Erythematosus
Peptide Hydrolases
Autoantibodies
Thrombotic Thrombocytopenic Purpura
von Willebrand Factor
Autoimmune Diseases
ADAMTS13 Protein
Antibodies

Keywords

  • ADAMTS-13
  • Systemic lupus erythematosus
  • Systemic sclerosis
  • Thrombotic microangiopathies
  • Von Willebrand factor V

ASJC Scopus subject areas

  • Hematology

Cite this

Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). / Mannucci, Pier Mannuccio; Vanoli, Massimo; Forza, Ileana; Canciani, Maria Teresa; Scorza, Raffaella.

In: Haematologica, Vol. 88, No. 8, 01.08.2003, p. 914-918.

Research output: Contribution to journalArticle

@article{24398ebe96c8435fa0b0ba04df99af6a,
title = "Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis)",
abstract = "Background and Objectives. Autoantibodies inactivating the von Willebrand factor (VWF) cleaving protease, ADAMTS-13, are among the most frequent causes of thrombotic thrombocytopenic purpura (TTP). We evaluated whether or not ADAMTS-13 deficiency and autoantibodies inactivating the protease prevalent in patients with the prototypic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Design and Methods. We measured, in parallel, the protease and VWF antigen (VWF:Ag) in 123 patients, 36 of whom had SLE and 87 of whom had SSc. In 14 patients with either disease who had low plasma protease levels (below 40{\%}) we also looked for anti-ADAMTS-13 inactivating antibodies. Results. ADAMTS-13 levels were significantly lower in SLE (p=0.0013) and in SSc (p=0.0002) than in normal controls. No anti-ADAMTS activity was measurable in patients with low ADAMTS-13 levels. VWF: Ag was high in both SLE and SSc (p=0.001). Interpretation and Conclusions. Systemic connective tissue diseases are other conditions besides TTP that are associated in some instances with low but detectable levels of ADAMTS-13. Autoantibodies inactivating protease activity are not the cause of the low plasma levels of ADAMTS-13.",
keywords = "ADAMTS-13, Systemic lupus erythematosus, Systemic sclerosis, Thrombotic microangiopathies, Von Willebrand factor V",
author = "Mannucci, {Pier Mannuccio} and Massimo Vanoli and Ileana Forza and Canciani, {Maria Teresa} and Raffaella Scorza",
year = "2003",
month = "8",
day = "1",
language = "English",
volume = "88",
pages = "914--918",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis)

AU - Mannucci, Pier Mannuccio

AU - Vanoli, Massimo

AU - Forza, Ileana

AU - Canciani, Maria Teresa

AU - Scorza, Raffaella

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background and Objectives. Autoantibodies inactivating the von Willebrand factor (VWF) cleaving protease, ADAMTS-13, are among the most frequent causes of thrombotic thrombocytopenic purpura (TTP). We evaluated whether or not ADAMTS-13 deficiency and autoantibodies inactivating the protease prevalent in patients with the prototypic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Design and Methods. We measured, in parallel, the protease and VWF antigen (VWF:Ag) in 123 patients, 36 of whom had SLE and 87 of whom had SSc. In 14 patients with either disease who had low plasma protease levels (below 40%) we also looked for anti-ADAMTS-13 inactivating antibodies. Results. ADAMTS-13 levels were significantly lower in SLE (p=0.0013) and in SSc (p=0.0002) than in normal controls. No anti-ADAMTS activity was measurable in patients with low ADAMTS-13 levels. VWF: Ag was high in both SLE and SSc (p=0.001). Interpretation and Conclusions. Systemic connective tissue diseases are other conditions besides TTP that are associated in some instances with low but detectable levels of ADAMTS-13. Autoantibodies inactivating protease activity are not the cause of the low plasma levels of ADAMTS-13.

AB - Background and Objectives. Autoantibodies inactivating the von Willebrand factor (VWF) cleaving protease, ADAMTS-13, are among the most frequent causes of thrombotic thrombocytopenic purpura (TTP). We evaluated whether or not ADAMTS-13 deficiency and autoantibodies inactivating the protease prevalent in patients with the prototypic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Design and Methods. We measured, in parallel, the protease and VWF antigen (VWF:Ag) in 123 patients, 36 of whom had SLE and 87 of whom had SSc. In 14 patients with either disease who had low plasma protease levels (below 40%) we also looked for anti-ADAMTS-13 inactivating antibodies. Results. ADAMTS-13 levels were significantly lower in SLE (p=0.0013) and in SSc (p=0.0002) than in normal controls. No anti-ADAMTS activity was measurable in patients with low ADAMTS-13 levels. VWF: Ag was high in both SLE and SSc (p=0.001). Interpretation and Conclusions. Systemic connective tissue diseases are other conditions besides TTP that are associated in some instances with low but detectable levels of ADAMTS-13. Autoantibodies inactivating protease activity are not the cause of the low plasma levels of ADAMTS-13.

KW - ADAMTS-13

KW - Systemic lupus erythematosus

KW - Systemic sclerosis

KW - Thrombotic microangiopathies

KW - Von Willebrand factor V

UR - http://www.scopus.com/inward/record.url?scp=0141649437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141649437&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 914

EP - 918

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -